Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Aldosterone Blockade in Heart Failure
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Justin Ezekowitz
- Target Recruit Count
- 8
- Registration Number
- NCT00523757
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2008-10-17
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 30
- Registration Number
- NCT00498537
- Locations
- 🇺🇸
VA Medical Center, Dayton, Dayton, Ohio, United States
The Efficacy of Spironolactone in Patients With Resistant Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2010-12-06
- Target Recruit Count
- 40
- Registration Number
- NCT00430794
- Locations
- 🇬🇧
Clinical Research Facility, Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom
Double Blind Crossover Comparison of Diuretics in the Young
- Conditions
- Low-Renin Hypertension
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2007-02-01
- Lead Sponsor
- University of Cambridge
- Target Recruit Count
- 30
- Registration Number
- NCT00429897
- Locations
- 🇬🇧
University of Cambridge - Addenbrookes Hospital, Cambridge, United Kingdom
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- Conditions
- Heart FailureVentricular Dysfunction, Left
- Interventions
- Drug: DiureticsDrug: HF treatment according to Swedish guidelinesProcedure: Blood samplesProcedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT00391846
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
Improving Outcomes in Patients With Kidney Disease Due to Diabetes
- Conditions
- DiabetesKidney DiseaseHypertension
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 92
- Registration Number
- NCT00381134
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: Study# 2 irbsesartan (IR), fixed dose
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 166
- Registration Number
- NCT00353652
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy
- Conditions
- Hypertension
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2008-06-05
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 17
- Registration Number
- NCT00335413
Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis
- Conditions
- Liver CirrhosisPortal Hypertension
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2010-06-04
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT00332904
- Locations
- 🇩🇰
Department of Clinical Physiology and Nuclear Medicine, and Department for Gastrointestinal Medicine, Hvidovre Hospital, Hvidovre, Denmark
Spironolactone Safety in Dialysis Patients
- Conditions
- End Stage Renal DiseaseCongestive Heart Failure
- Interventions
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- State University of New York - Upstate Medical University
- Registration Number
- NCT00328809
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.